User profiles for Arife Ulas

Arife Ulas

SBÜ Bursa Şehir uygulama ve araştırma hastanesi
Verified email at sbu.edu.tr
Cited by 873

[HTML][HTML] Bone metastasis from gastric cancer: the incidence, clinicopathological features, and influence on survival

FP Turkoz, M Solak, S Kilickap, A Ulas… - Journal of Gastric …, 2014 - ncbi.nlm.nih.gov
Purpose To evaluate the incidence, clinicopathological characteristics, treatment outcomes,
prognostic factors, and survival of gastric cancer patients with bone metastases. Materials …

[PDF][PDF] Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant …

A Ulas, N Avci, T Kos, E Cubukcu, OF Olmez, N Bulut… - lung cancer, 2015 - jbuon.com
Purpose: To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the
platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-…

[HTML][HTML] A laboratory prognostic index model for patients with advanced non-small cell lung cancer

A Ulas, FP Turkoz, K Silay, S Tokluoglu, N Avci… - PLoS …, 2014 - journals.plos.org
Purpose We aimed to establish a laboratory prognostic index (LPI) in advanced non-small
cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to …

Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey

A Ulas, K Silay, S Akinci, D Dede… - … Pacific Journal of …, 2015 - avesis.medipol.edu.tr
Background: Medication errors in oncology may cause severe clinical problems due to low
therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate …

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases

A Ulas, A Bilici, A Durnali, S Tokluoglu, S Akinci… - Tumor Biology, 2016 - Springer
Skeletal-related events (SREs) for nonsmall cell lung cancer (NSCLC) patients with bone
metastasis lead to serious morbidity. The aim of this study was to determine risk factors for …

Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)

B Cetin, M Benekli, I Turker, L Koral, A Ulas… - Journal of …, 2014 - Taylor & Francis
Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor
type 2 (HER2/neu) and epidermal growth factor receptor (EGFR). The present study …

[PDF][PDF] Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients …

…, S Tolunay, E Cubukcu, O Fatih Olmez, A Ulas… - J BUON, 2015 - jbuon.com
Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical
markers in breast cancer specimens remains controversial. We designed the current study to …

Lung cancer in women, a different disease: survival differences by sex in Turkey

A Ulas, S Tokluoglu, M Kos, K Silay… - Asian Pacific Journal …, 2015 - koreascience.kr
Purpose: In this study, we aimed to evaluate the effects of sex-based non-small cell lung
cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study was …

Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology

…, S Yaman, O Gumusay, O Unal, A Ulas… - Asian Pacific Journal …, 2012 - avesis.gazi.edu.tr
Background: The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose
oral etoposide as an advanced treatment option in patients with platinum resistant …

Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

…, S Yuksel, M Inanc, O Bal, T Akman, D Yazilitas, A Ulas… - The Breast, 2016 - Elsevier
Purpose The aim of this study was to determine risk factors for brain metastasis as the first site
of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who …